Latviski English

Previous research studies

Projects in 2018.

„Etiology of severe influenza infection in Northern Europe (NorthernFlu)”. The main goal of the project is to decipher etiology of severe influenza virus (IV) infections in Northern Europe. Research is funded by the project “MOBTT39: Towards better diagnostics and treatment of severe influenza infections” (NorthernFlu), funder: European Regional Development Fund, Research Council of Estonia under Mobilitas+ programme” resources, study subject recruitment is partly supported by Genome Database of Latvian popualtion. Approval by Central Medical Ethics Committee No: 1/18-01-24.

„Development of unified therapeutic observance model for patients with inflammatory bowel disease using immunologic, molecular biology and morphological methods". Aim of the project is to study individual differences in tiopurine metabolism and terapeutic survilance  using immunological, clinical, molecular and morphological methods, in patients with inflammatory bowel disease. Support from University of Latvia "Microtiks" grant funds. Approval by Central Medical Ethics Committee No: 3/18-02-21.

"Investigation of interaction of smoked dietary products with gut microbiome”. Aim of the project is multidimensional investigation of the impact smoked food especially fish consumption exerts on human gut microbiome to gain insight in the responding functional pathways and metabolic consequences. Research is funded by the ERDF No.1.1.1.2/VIAA/1/16/128 project. Approval by Central Medical Ethics Committee No: 1/18-06-07.

“Walk healthy”. The aim is to improve physical abilities, diabetes control and lower complication risks with regular physical activities programm and interval training method in type two diabetes patients. Project will also help to evaluate use of mobile devices and efectivity in training monitoring in comparison with physiotherapist guided training. Principal investigator: Dr. med. JeļizaApproval by Central Medical Ethics Committee No:veta Sokolovska. Funding: LLC “Mikrotīkls” donation in framework of Fund of University of Latvia project. Ethical approval from University of Latvia Cardiology and Regenerative Medicine Insistute, Ethics committee of clinical-physiological, drug and pharmaceuticals research, approval  No: 28.06.17 - Prot. 6

“Study of DNS integrity of Latvian population in relation to age, gender, life style and pathologies". The aim is to study DNA integrity sage in population of Latvia depending on various factors (gender, age, life style and health condition), to investigate association between DNS integrity and DNS reparation gene polymorphisms. Principal investigator: Prof.  Nikolajs Sjakste. Approval by Central Medical Ethics Committee No: 1/17-10-10

"Identification of genetic markers involved in development of metastases and second cancers in melanoma (GENMEL)", Funding: ERA-NET on Translational Cancer Research (TRANSCAN) Joint Transnational Call for Proposals 2013 (JTC 2013) on: "Translational research on tertiary prevention in cancer patients", Project No.: GENMEL Z/15/1285 - PRL15/15, Period: 36 months (1st May 2015 – 30st April 2018). The aim is to identify genetic alterations having a prognostic value in development of metastases and second melanomas in asymptomatic patients that have undergone surgical treatment for primary cutaneous melanoma.

„Molecular design of new luminescent compounds for diagnostic purposes”, Funding: European Regional Development Fund (ERDF), Measure 1.1.1.1 “Industry-Driven Research”, Project Nr.: 1.1.1.1/16/A/211, Period: 1st March 2017 – 29 st February 2020. The project is aimed to the synthesis of new luminescent substances for the development of diagnostics methods in medicine and veterinary medicine.

The National Research programme „Biomedicine for Public Health” (BIOMEDICINE), Project: No 2 „Molecular Mechanisms, Pharmacogenetics and New Medicines for Treatment of Diabetes and Cardiovascular Complications”, Programme implementation period: 2014-2017. Targets of the project: To gain scientific competence in public health by clinical, biomedical and health habit studies along with development of new diagnostic tools and medicines to reach enhancement in treatment and prophylaxis of diabetic complications aiming general improvement of public health.

„Molecular markers of pituitary tumor development, progression and therapy response”, Funding:  European Regional Development Fund (ERDF), Measure 1.1.1.1 “Industry-Driven Research”, Project No: 1.1.1.1/16/A/066, Period: 1st January 2017 – 31 st December 2019. The main objective of this project is to investigate molecular determinants of pituitary adenoma development and progression and to identify the crucial factors linked to variability in clinical outcome that could further be applied as biomarkers for improvement of pituitary tumor treatment therapies.

„Investigation of interplay between multiple determinants influencing response to metformin: search for reliable predictors for efficacy of type 2 diabetes therapy”, Funding: European Regional Development Fund (ERDF), Measure 1.1.1.1 “Industry‑Driven Research”, Project No: 1.1.1.1/16/A/091, Period: 1st January 2017 – 31st December 2019. The objective of the project is to explore underinvestigated factors characterizing response to metformin with the aim to identify reliable biomarkers of efficacy and tolerability of metformin in the treatment of type 2 diabetes (T2D).

"LatDiane: Latvian Diabetic Nephropaty study", Funded by Basic funding form University of Latvia. Aim determine nitric oxide in type one diabetes patients serum and urine.

“Determination of genetic, epigenetic and clinical proteosomal markers of multiple sclerosis”, Funding: European Regional Development Fund (ERDF) 1.1.1.1/16/A/016. The aim of the project is to obtain novel findings about the role of proteosomal genetic, genomics and clinical importance in pathogenesis of multiple sclerosis and to obtain knowledge and skills for medical and pharmacogenomical application.

Projects in 2017.

 "Identification of genetic markers involved in development of metastases and second cancers in melanoma (GENMEL)", Funding: ERA-NET on Translational Cancer Research (TRANSCAN) Joint Transnational Call for Proposals 2013 (JTC 2013) on: "Translational research on tertiary prevention in cancer patients", Project No.: GENMEL Z/15/1285 - PRL15/15, Period: 36 months (1st May 2015 – 30st April 2018). The aim is to identify genetic alterations having a prognostic value in development of metastases and second melanomas in asymptomatic patients that have undergone surgical treatment for primary cutaneous melanoma.

„Molecular design of new luminescent compounds for diagnostic purposes”, Funding: European Regional Development Fund (ERDF), Measure 1.1.1.1 “Industry-Driven Research”, Project Nr.: 1.1.1.1/16/A/211, Period: 1st March 2017 – 29 st February 2020. The project is aimed to the synthesis of new luminescent substances for the development of diagnostics methods in medicine and veterinary medicine.

The National Research programme „Biomedicine for Public Health” (BIOMEDICINE), Project: No 2 „Molecular Mechanisms, Pharmacogenetics and New Medicines for Treatment of Diabetes and Cardiovascular Complications”, Programme implementation period: 2014-2017. Targets of the project: To gain scientific competence in public health by clinical, biomedical and health habit studies along with development of new diagnostic tools and medicines to reach enhancement in treatment and prophylaxis of diabetic complications aiming general improvement of public health.

„Molecular markers of pituitary tumor development, progression and therapy response”, Funding:  European Regional Development Fund (ERDF), Measure 1.1.1.1 “Industry-Driven Research”, Project No: 1.1.1.1/16/A/066, Period: 1st January 2017 – 31 st December 2019. The main objective of this project is to investigate molecular determinants of pituitary adenoma development and progression and to identify the crucial factors linked to variability in clinical outcome that could further be applied as biomarkers for improvement of pituitary tumor treatment therapies.

„Investigation of interplay between multiple determinants influencing response to metformin: search for reliable predictors for efficacy of type 2 diabetes therapy”, Funding: European Regional Development Fund (ERDF), Measure 1.1.1.1 “Industry‑Driven Research”, Project No: 1.1.1.1/16/A/091, Period: 1st January 2017 – 31st December 2019. The objective of the project is to explore underinvestigated factors characterizing response to metformin with the aim to identify reliable biomarkers of efficacy and tolerability of metformin in the treatment of type 2 diabetes (T2D).

"LatDiane: Latvian Diabetic Nephropaty study", Funded by Basic funding form University of Latvia. Aim determine nitric oxide in type one diabetes patients serum and urine.

“Determination of genetic, epigenetic and clinical proteosomal markers of multiple sclerosis”, Funding: European Regional Development Fund (ERDF) 1.1.1.1/16/A/016. The aim of the project is to obtain novel findings about the role of proteosomal genetic, genomics and clinical importance in pathogenesis of multiple sclerosis and to obtain knowledge and skills for medical and pharmacogenomical application.

 

Information about studies, that have been carried out before 2017 are stored in LGDB archive.

 

For the preparation of these research articles recources of Genome Database of Latvian population was used:

Year 2018.

Ozola A., Ruklisa D., Pjanova D. Association of the 16q24.3 region gene variants rs1805007 and rs4785763 with heightened risk of melanoma in Latvian population. Meta Gene (2018) 18:87-92.

Grasmane A., Rots D., Vitina Z, Magomedova V, Gailite L. The association of FMR1 gene (CGG)n variation with idiopathic female infertility.Archives of Medical Sciences (pieņemts publikācijai 2018,gadā, publicēšana 2019/2020 gadā).

Gailite, L., Rots, D., Pukite, I., Cernevska, G., Kreile, M. Case report: multiple UGT1A1 gene variants in a patient with Crigler-Najjar syndrome. BMC Pediatrics, Volume 18, Issue 1, 3 October 2018, 317. doi: 10.1186/s12887-018-1285-6.

Moisejevs G., Gailite L., Isajevs S., Nikitina Zake L., Kempa I., Janciauskis D., Kikuste I., Sivins A., Ancans G., Leja M. Lack of association between rs2067474 in the histamine receptor H2 gene and gastric cancer in Latvian population. Latvian Science Proceedings (pieņemts publicēšanai)

Elbere I, Silamikelis I, Ustinova M, Kalnina I, Zaharenko L, Peculis R, Konrade I, Ciuculete DM, Zhukovsky C, Gudra D, Radovica-Spalvina I, Fridmanis D, Pirags V, Schiöth HB, Klovins J 2018. Significantly altered peripheral blood cell DNA methylation profile as a result of immediate effect of metformin use in healthy individuals. Clinical Epigenetics DOI: 10.1186/s13148-018-0593-xiT scalled.

Ustinova M, Silamikelis I, Elbere I, Kalnina I, Ansone L, Rovite V, Radovica-Spalvina I, Fridmanis D, Aladyeva J, Konrade I, Pirags V, Klovins J. Metformin Strongly Affects Transcriptome of Peripheral Blood Cells in Healthy Individuals” (Iesniegta publicēšanai Scientific Reports)

Elbere I, Kalnina I, Silamikelis I, Konrade I, Zaharenko L, Sekace K, Radovica-Spalvina I, Fridmanis D, Gudra D, Pirags V, Klovins J. (2018) Association of metformin administration with gut microbiome dysbiosis in healthy volunteers. PLoS ONE 13(9): e0204317.

Tambets K, Yunusbayev B, Hudjashov G, Ilumäe AM, Rootsi S, Honkola T, Vesakoski O, Atkinson Q, Skoglund P, Kushniarevich A, Litvinov S, Reidla M, Metspalu E, Saag L, Rantanen T, Karmin M, Parik J, Zhadanov SI, Gubina M, Damba LD, Bermisheva M, Reisberg T, Dibirova K, Evseeva I, Nelis M, Klovins J, Metspalu A, Esko T, Balanovsky O, Balanovska E, Khusnutdinova EK, Osipova LP, Voevoda M, Villems R, Kivisild T, Metspalu M. Genes reveal traces of common recent demographic history for most of the Uralic-speaking populations. Genome Biol. 2018 Sep 21;19(1):139.

Ni G, Gratten J, Wray NR, Lee SH; Schizophrenia Working Group of the Psychiatric Genomics Consortium. Age at first birth in women is genetically associated with increased risk of schizophrenia. Sci Rep. 2018 Jul 5;8(1):10168.

Brainstorm Consortium; Analysis of shared heritability in common disorders of the brain. Science. 2018 Jun 22;360(6395).

Bipolar Disorder and Schizophrenia Working Group of the Psychiatric Genomics Consortium. Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes. Cell. 2018 Jun 14;173(7):1705-1715

Ni G, Moser G; Schizophrenia Working Group of the Psychiatric Genomics Consortium, Wray NR, Lee SH. Estimation of Genetic Correlation via Linkage Disequilibrium Score Regression and Genomic Restricted Maximum Likelihood. Am J Hum Genet. 2018 Jun 7;102(6):1185-1194

Year 2017.

McLaughlin RL, Schijven D, van Rheenen W, van Eijk KR, O'Brien M, Kahn RS, Ophoff RA, Goris A, Bradley DG, Al-Chalabi A, van den Berg LH, Luykx JJ, Hardiman O, Veldink JH; Project MinE GWAS Consortium; Schizophrenia Working Group of the Psychiatric Genomics Consortium. Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. Nat Commun. 2017 Mar 21;8:14774.

Sviklāne L, Olmane E, Dzērve Z, Kupčs K, Pīrāgs V V, Sokolovska J. Fatty liver index and hepatic steatosis index predict non-alcoholic fatty liver disease in type 1 diabetes. J Gastroenterol Hepatol. 2017 May 2.

A New Baltic Population-Specific Human Genetic Marker in the PMCA4 Gene. Stavusis J, Inashkina I, Lace B, Pelnena D, Limborska S, Khrunin A, Kucinskas V, Krumina A, Piekuse L, Zorn B, Fodina V, Punab M, Erenpreiss J. Hum Hered. 2016;82(3-4):140-146. doi: 10.1159/000481434. Epub 2017 Nov 2.

Rovite V, Wolff-Sagi Y, Zaharenko L, Nikitina-Zake L, Grens E, Klovins J. Genome Database of the Latvian Population (LGDB): design, goals, and primary results. Journal of Epidemiology. Accepted August 6th, 2017, in press.

Ilze Elbere, Ineta Kalnina, Ivars Silamikelis, Ilze Konrade, Linda Zaharenko, Ilze Radovica-Spalvina, Davids Fridmanis, Dita Gudra, Valdis Pirags, Janis Klovins. Association of metformin administration with gut microbiome dysbiosis in healthy volunteers. The Journal of Pharmacology and Experimental Therapeutics.

Year 2016.

Dujic, T., Zhou, K., Yee, S.W., van Leeuwen N., de Keyser, C.E., Javorský, M., Goswami, S., Zaharenko. L., Marie, M., Christensen, H., Out, M., Tavendale, R., Kubo, M., Hedderson, M.M., van der Heijden, A.A., Klimčáková, L., Pirags, V., Kooy, A., Brøsen, K., Klovins, J., Semiz, S., Tkáč, I., Stricker, B.H., Palmer, C.N., 't Hart, L.M., Giacomini, K.M., Pearson, E.R. Variants in Pharmacokinetic Transporters and Glycaemic Response to Metformin: A MetGen Meta-Analysis. 2016. Clinical Pharmacology & Therapeutics, Epub ahead of print. PMID: 27859023

Zaharenko, L., Kalnina, I., Geldnere, K., Konrade, I., Grinberga, S., Židzik ,J., Javorský, M., Lejnieks, A., Nikitina-Zake, L., Fridmanis, D., Peculis, R., Radovica-Spalvina, I., Hartmane, D., Pugovics, O., Tkáč, I., Klimčáková, L., Pirags, V., Klovins, J. Single nucleotide polymorphisms in the intergenic region between metformin transporter OCT2 and OCT3 genes are associated with short-term response to metformin monotherapy in type 2 diabetes mellitus patients. 2016. European Journal of Endocrinology, Epub ahead of print. PMID: 27609360

Peculis, R., Balcere, I., Rovite, V., Megnis, K., Valtere, A., Stukens, J., Arnicane, L., Nikitina-Zake, L., Lejnieks, A., Pirags, V., Klovins, J. Polymorphisms in MEN1 and DRD2 genes are associated with the occurrence and characteristics of pituitary adenomas (2016) European Journal of Endocrinology, 175 (2), pp. 145-153. PMID: 27185868

Franke, B., Stein, J.L., Ripke, S., Anttila, V., Hibar, D.P., van Hulzen, K.J., Arias-Vasquez, A., Smoller, J.W., Nichols, T.E., Neale, M.C., McIntosh, A.M., Lee, P., McMahon, F.J., Meyer-Lindenberg, A., Mattheisen, M., Andreassen, O.A., Gruber, O., Sachdev, P.S., Roiz-Santiañez, R., Saykin, A.J., Ehrlich, S., Mather, K.A., Turner, J.A., Schwarz, E., Thalamuthu, A., Yao, Y., Ho, Y.Y., Martin, N.G., Wright, M.J., Schizophrenia Working Group of the Psychiatric Genomics Consortium, Psychosis Endophenotypes International Consortium, Wellcome Trust Case Control Consortium 2, Enigma Consortium, O'Donovan, M.C., Thompson, P.M., Neale, B.M., Medland, S.E., Sullivan, P.F. Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof of concept (2016) Nature Neuroscience, 19(3):420-31. PMID: 26854805

Sekar, A., Bialas, A.R., de Rivera, H., Davis, A., Hammond, T.R., Kamitaki, N., Tooley, K., Presumey, J., Baum, M., Van Doren, V., Genovese, G., Rose, S.A., Handsaker, R.E., Schizophrenia Working Group of the Psychiatric Genomics Consortium, Daly, M.J., Carroll, M.C., Stevens, B., McCarroll, S.A. Schizophrenia risk from complex variation of complement component 4 (2016). Nature, 530(7589):177-83. PMID: 26814963

Bigdeli, T.B., Ripke, S., Bacanu, S.A., Lee, S.H., Wray, N.R., Gejman, P.V., Rietschel, M., Cichon, S., St Clair, D., Corvin, A., Kirov, G., McQuillin, A., Gurling, H., Rujescu, D., Andreassen, O.A., Werge, T., Blackwood, D.H., Pato, C.N., Pato, M.T., Malhotra, A.K., O'Donovan, M.C., Kendler, K.S., Fanous, A.H., Schizophrenia Working Group of the Psychiatric Genomics Consortium. Genome-wide association study reveals greater polygenic loading for schizophrenia in cases with a family history of illness (2016) American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 171B(2):276-89. PMID: 26663532

Hamdi, Y., .... Tihomirova, L., ..... Simard, J. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3 (2016) Breast Cancer Research and Treatment, pp. 1-18. PMID: 27796716

Lawrenson, K., … Tihimirova, L., ... Price, M. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus (2016) Nature Communications, 7, art. no. 12675. PMID: 27601076

Hollestelle, A.,…. Tihomirova, L., … Goode, E.L., Breast Cancer Family Register, EMBRACE, GENICA Network, HEBON, SWE-BRCA No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer (2016) Gynecologic Oncology, 141 (2), pp. 386-401. PMID: 25940428

Couch, F.J.,…, Tihomirova, L., …. Antoniou, A.C. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer (2016) Nature Communications, 7, art. no. 11375. PMID:     27117709

Dunning, A.M.,… Tihomirova, L., … Edwards, S.L. Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170 (2016) Nature Genetics, 48 (4), pp. 374-386. PMID: 26928228

Meeks, H.D., …. Tihomirova, L., … Goldgar, D.E. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers (2016) Journal of the National Cancer Institute, 108 (2), art. no. Djv315. PMID: 26586665

Inashkina, I., Jankevics, E., Stavusis, J., Vasiljeva, I., Viksne, K., Micule, I., Strautmanis, J., Naudina, M.S., Cimbalistiene, L., Kucinskas, V., Krumina, A., Utkus, A., Burnyte, B., Matuleviciene, A., Lace, B.

Robust genotyping tool for autosomal recessive type of limb-girdle muscular dystrophies (2016) BMC Musculoskeletal Disorders, 17 (1), art. no. 1058. PMID: 27142102

Igumnova, V., Capligina, V., Krams, A., Cirule, A., Elferts, D., Pole, I., Jansone, I., Bandere, D., Ranka, R. Genotype and allele frequencies of isoniazid-metabolizing enzymes NAT2 and GSTM1 in Latvian tuberculosis patients (2016) Journal of Infection and Chemotherapy, 22 (7), pp. 472-477. PMID: 27236516

Information about publications, that have been published before 2016 are stored in LGDB archive